Demo
ABEO Nasdaq· Abeona Therapeutics Inc.
FundamentalsNews digest Peer analysis
Login
ABEO Nasdaq· Abeona Therapeutics Inc.
Earnings report Q3 2023

ABEO Reports Decrease in Revenue for the Latest Quarter

Segments of revenue

ABEO's revenue for the latest quarter was primarily derived from license and other revenues, which amounted to $3.5 million. There were no revenues reported in the previous year's corresponding quarter.

Strengths

ABEO's revenue from license and other sources increased significantly compared to the previous year, indicating potential growth opportunities in these areas. The management comments in the report did not provide specific explanations for the increase in revenue.

Challenges

ABEO faced challenges in terms of expenses, with total expenses amounting to $11.33 million for the latest quarter. This represents an increase from the previous year's corresponding quarter, where total expenses were $9.38 million. The increase in expenses can be attributed to higher research and development costs, general and administrative expenses, and impairment charges.

Noteworthy

ABEO reported a loss from operations of $11.33 million for the latest quarter, compared to a loss of $9.38 million in the previous year's corresponding quarter. However, the company did report a positive interest income of $593,000, indicating some financial stability.

Summary

ABEO's latest quarter performance showed a decrease in revenue, primarily driven by license and other revenues. The company faced challenges in managing expenses, resulting in a loss from operations. However, ABEO reported positive interest income, which provides some financial stability. The increase in expenses can be attributed to higher research and development costs, general and administrative expenses, and impairment charges. Overall, ABEO's financial performance in the latest quarter reflects the need for cost management and potential growth opportunities in license and other revenue sources.

Source documents

Form 10-Q  filed on Nov 13, 2023
135 pages scanned

Reference data

Company financials Q3 revenue 0
Analyst estimates Q3 EPS missed by -11.07%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.